Saturday, 31 October 2026European Markets

SOLVAC NOM(RETAIL) And ROBERTET CI Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

Loading stream...

(vianews) - solvac nom(retail) (solv.br) is among this list of stock assets with the highest dividend rate and return on equity on the chemicals industry.

financial asset price forward dividend yield return on equity
solvac nom(retail) (solv.br) €114.00 4.47% 11.29%
robertet ci (cbe.pa) €760.90 1.05% 13.85%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. solvac nom(retail) (solv.br)

4.47% forward dividend yield and 11.29% return on equity

solvac s.a. operates as an advanced materials and specialty chemicals company in belgium. it offers specialty polymers, composite materials, soda ash, peroxides, silica, and coatis. the company was incorporated in 1983 and is headquartered in brussels, belgium.

earnings per share

as for profitability, solvac nom(retail) has a trailing twelve months eps of €19.

pe ratio

solvac nom(retail) has a trailing twelve months price to earnings ratio of 6. meaning, the purchaser of the share is investing €6 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.29%.

volume

today's last reported volume for solvac nom(retail) is 224 which is 81.95% below its average volume of 1241.

dividend yield

according to morningstar, inc., the next dividend payment is on dec 27, 2023, the estimated forward annual dividend rate is 4.92 and the estimated forward annual dividend yield is 4.47%.

revenue growth

year-on-year quarterly revenue growth declined by 57.6%, now sitting on 410.1m for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, solvac nom(retail)'s stock is considered to be oversold (<=20).

more news about solvac nom(retail).

2. robertet ci (cbe.pa)

1.05% forward dividend yield and 13.85% return on equity

robertet sa produces and sells perfumes, aromas, and natural products. the company operates in four segments: raw materials, fragrances, flavors, and active ingredients. it also produces organic essential oils and active ingredients. the company operates in north america, europe, the asia pacific, south america, caribbean, africa, and the middle east. robertet sa was founded in 1850 and is headquartered in grasse, france.

earnings per share

as for profitability, robertet ci has a trailing twelve months eps of €36.02.

pe ratio

robertet ci has a trailing twelve months price to earnings ratio of 21.12. meaning, the purchaser of the share is investing €21.12 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.85%.

volatility

robertet ci's last week, last month's, and last quarter's current intraday variation average was a negative 1.45%, a negative 0.44%, and a positive 2.55%.

robertet ci's highest amplitude of average volatility was 1.45% (last week), 2.67% (last month), and 2.55% (last quarter).

moving average

robertet ci's value is under its 50-day moving average of €768.10 and below its 200-day moving average of €781.37.

yearly top and bottom value

robertet ci's stock is valued at €760.90 at 06:40 est, below its 52-week high of €831.60 and higher than its 52-week low of €702.00.

more news about robertet ci.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com